4 active not recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
Follow folfirinox: new trials by email Literature Review of folfirinox trials Research Report on folfirinox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Redefining FOLFIORINOX in Older Pancreatic Cancer Patients FOLFIRINOX - Metastatic Pancreatic Cancer | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 37 | 2022-04-22 | 2026-10-29 |
| Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma Folfirinox, Gemcitabine, radiation therapy - Pancreas Cancer | Phase 2 | Active not recruiting | University of Cincinnati | 32 | 2021-03-17 | 2026-08-11 |
| Saltikva for Metastatic Pancreatic Cancer Salmonella-IL2, FOLFIRINOX Alone (Historical Controls), Gemcitabine/Abraxane Alone (Historical Controls) - Metastatic Pancreatic Cancer | Phase 2 | Active not recruiting | Salspera LLC | 60 | 2020-10-20 | 2026-05-14 |
| Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer FOLFIRINOX, Losartan, Nivolumab - Pancreatic Cancer | Phase 2 | Active not recruiting | Massachusetts General Hospital | 168 | 2018-08-10 | 2025-10-01 |
Fox Chase Cancer Center (1) · Massachusetts General Hospital (1) · Salspera LLC (1) · University of Cincinnati (1)
United States (3) · Canada (1)
Davendra Sohal, Sohal (1) · Gerald Batist, MD (1) · Jennifer Y. Wo, MD (1)